Evaluation and Mitigation of Time‐Dependent Confounding Effects in Conventional Exposure‐Response Analyses for Oncology Drugs
CPT: Pharmacometrics & Systems Pharmacology · 2025-12 · 14 (12) · 2118-2127
DOI: 10.1002/psp4.70119 ↗Abstract
ABSTRACT Conventional exposure–response (E–R) analyses, such as logistic regression and time‐to‐event analysis using summary exposure metrics, are often conducted in oncology using data from the pivotal trial(s) with a single dose level to support dosing decisions. However, these E–R analyses, affected by multiple confounding factors, may mischaracterize true E–R relationships, potentially limiting their utility in dosing decisions. This study investigates potential mischaracterization in such analyses influenced by the following time‐dependent confounding factors: exposure accumulation, dose modification patterns, and event onset time. We used a simulation‐based approach to evaluate two E–R scenarios: ER1, where event time generated with a Weibull distribution is not affected by drug exposure, and ER2, where the response is driven by drug exposure via a joint PK‐tumor size model. Our analyses indicate that when using time‐dependent exposure metrics (e.g., average concentration till event/censoring), exposure accumulation tends to induce an inverse E–R trend, while dose modifications (interruptions/reductions) likely induce a positive E–R trend. Simulations suggest that employing static exposure metrics (e.g., first‐cycle or steady‐state) minimizes these biases. Additionally, adopting an E max model aligned with the underground truth in ER2 in the E–R analyses could reduce bias. When significant dose modifications are present, including relevant data from a dose‐range study and employing modified methods for time‐dependent exposure derivation may help mitigate bias. Overall, using multiple exposure metrics (including static ones) to assess E–R consistency and interpreting the potential causal effects with totality of evidence (including dose–response results) should be implemented to better inform dosing decisions.
EUVIMED